Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus

Journal of Clinical Investigation

Volumn 120, Issue 6, 2010, Pages 2194-2205

  Echeverry, Ramiro ^a   Wu, Jialing ^a,b   Haile, Woldeab B ^a   Guzman, Johanna ^a   Yepes, Manuel ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEATH; BRAIN HYPOXIA; BRAIN ISCHEMIA; CONTROLLED STUDY; HIPPOCAMPUS; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BRAIN; CELL DEATH; CELL HYPOXIA; FIBRINOLYSIN; FIBRINOLYTIC AGENTS; HIPPOCAMPUS; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS; PLASMINOGEN ACTIVATORS; SERINE PROTEASES; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77953182892     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI41722     Document Type: Article

References (44)

1. Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJ, Degen JL. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell. 1996;87(4):709-719.
2. Nassar T, et al. In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood. 2004; 103(3):897-902. (Pubitemid 38129548)
3. Polavarapu R, et al. Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood. 2007;109(8):3270-3278. (Pubitemid 46572512)
4. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest. 2003;112(10):1533-1540. (Pubitemid 38056279)
5. Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature. 1993;361(6411):453-457. (Pubitemid 23050134)
6. Seeds NW, Williams BL, Bickford PC. Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science. 1995;270(5244):1992-1994.
7. Yepes M, et al. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest. 2002;109(12):1571-1578. (Pubitemid 34663519)
8. Mataga N, Nagai N, Hensch TK. Permissive proteolytic activity for visual cortical plasticity. Proc Natl Acad Sci U S A. 2002;99(11):7717-7721. (Pubitemid 34568757)
9. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature. 1995;377(6547):340-344.
10. Yepes M, et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood. 2000;96(2):569-576. (Pubitemid 30463377)
11. Bingman VP. The importance of comparative studies and ecological validity for understanding hippocampal structure and cognitive function. Hippocampus. 1992;2(3):213-219.
12. Wilde GJ, Pringle AK, Wright P, Iannotti F. Differential vulnerability of the CA1 and CA3 subfields of the hippocampus to superoxide and hydroxyl radicals in vitro. J Neurochem. 1997;69(2):883-886. (Pubitemid 27327995)
13. Sappino AP, et al. Extracellular proteolysis in the adult murine brain. J Clin Invest. 1993;92(2):679-685.
14. Salles FJ, Strickland S. Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus. J Neurosci. 2002;22(6):2125-2134. (Pubitemid 35386512)
15. Kitagawa K, et al. 'Ischemic tolerance' phenomenon detected in various brain regions. Brain Res. 1991;561(2):203-211.
16. Matsushima K, Hakim AM. Transient forebrain ischemia protects against subsequent focal cerebral ischemia without changing cerebral perfusion. Stroke. 1995;26(6):1047-1052.
17. Grabb MC, Choi DW. Ischemic tolerance in murine cortical cell culture: critical role for NMDA receptors. J Neurosci. 1999;19(5):1657-1662.
18. Soriano FX, Papadia S, Hofmann F, Hardingham NR, Bading H, Hardingham GE. Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J Neurosci. 2006;26(17):4509-4518. (Pubitemid 44315350)
19. Nicole O, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med. 2001;7(1):59-64. (Pubitemid 32095643)
20. Samson AL, et al. Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function. J Neurochem. 2008;107(4):1091- 1101.
21. Pawlak R, Magarinos AM, Melchor J, McEwen B, Strickland S. Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior. Nat Neurosci. 2003;6(2):168-174. (Pubitemid 36182786)
22. Samson AL, Medcalf RL. Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron. 2006;50(5):673-678.
23. Zhang X, Polavarapu R, She H, Mao Z, Yepes M. Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein mediate cerebral ischemia-induced nuclear factor-kappaB pathway activation. Am J Pathol. 2007;171(4):1281-1290. (Pubitemid 47582901)
24. Zhang C, An J, Strickland DK, Yepes M. The low-density lipoprotein receptor-related protein 1 mediates tissue-type plasminogen activator-induced microglial activation in the ischemic brain. Am J Pathol. 2009;174(2):586-594.
25. Liot G, et al. 2,7-Bis-(4-amidinobenzylidene)-cycloheptan-1-one dihydrochloride, tPA stop, prevents tPA-enhanced excitotoxicity both in vitro and in vivo. J Cereb Blood Flow Metab. 2004;24(10):1153-1159. (Pubitemid 39332154)
26. Chen M, et al. Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke. 2008;39(11):3042-3048.
27. Liu Y, et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci. 2007;27(11):2846-2857. (Pubitemid 46438991)
28. Yuan H, et al. The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors. J Biol Chem. 2009;284(19):12862-12873.
29. Skrzypiec AE, Maiya R, Chen Z, Pawlak R, Strickland S. Plasmin-mediated degradation of laminin gamma-1 is critical for ethanol-induced neurodegeneration. Biol Psychiatry. 2009;66(8):785-794.
30. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med. 1998;4(2):228-231. (Pubitemid 28138083)
31. Kim YH, Park JH, Hong SH, Koh JY. Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator. Science. 1999;284(5414):647-650. (Pubitemid 29289590)
32. Liot G, et al. Tissue-type plasminogen activator rescues neurones from serum deprivation-induced apoptosis through a mechanism independent of its proteolytic activity. J Neurochem. 2006;98(5):1458-1464. (Pubitemid 44200437)
33. Kobayashi S, Harris VA, Welsh FA. Spreading depression induces tolerance of cortical neurons to ischemia in rat brain. J Cereb Blood Flow Metab. 1995;15(5):721-727.
34. Kapinya KJ, et al. Tolerance against ischemic neuronal injury can be induced by volatile anesthetics and is inducible NO synthase dependent. Stroke. 2002;33(7):1889-1898.
35. Tasaki K, Ruetzler CA, Ohtsuki T, Martin D, Nawashiro H, Hallenbeck JM. Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats. Brain Res. 1997; 748(1-2):267-270. (Pubitemid 27094913)
36. Calabresi P, et al. Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. Eur J Neurosci. 2000;12(3):1002-1012.
37. Ho-Tin-Noe B, Enslen H, Doeuvre L, Corsi JM, Lijnen HR, Angles-Cano E. Role of plasminogen activation in neuronal organization and survival. Mol Cell Neurosci. 2009;42(4):288-295.
38. Flavin MP, Zhao G. Tissue plasminogen activator protects hippocampal neurons from oxygen-glucose deprivation injury. J Neurosci Res. 2001;63(5):388-394.
39. Neyton J, Paoletti P. Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci. 2006;26(5):1331-1333.
40. Frizelle PA, Chen PE, Wyllie DJ. Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquino xalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: implications for studies of synaptic transmission. Mol Pharmacol. 2006;70(3):1022-1032.
41. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13(22):2905-2927.
42. Dudek H, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 1997;275(5300):661-665.
43. Yano S, et al. Activation of Akt/protein kinase B contributes to induction of ischemic tolerance in the CA1 subfield of gerbil hippocampus. J Cereb Blood Flow Metab. 2001;21(4):351-360.
44. Murakami K, Kondo T, Epstein CJ, Chan PH. Overexpression of CuZn-superoxide dismutase reduces hippocampal injury after global ischemia in transgenic mice. Stroke. 1997;28(9):1797-1804.